What did the speaker highlight about the EXCALIBER trial results, presented as a plenary at this meeting?
A large MRD-negativity benefit, much greater than expected, with a presumed PFS benefit
A significant overall survival benefit, but no difference in MRD negativity
Efficacy similar to standard therapy, but with better tolerability